Mitapivat
Beta-Thalassemia Major
Agios Pharmaceuticals, Inc.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
30 Active assets in the Beta-Thalassemia Major cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deferasirox Pakistan Blood and Marrow Transplant (PBMT) Group | Phase 4 | BBB |
Deferiprone Pakistan Blood and Marrow Transplant (PBMT) Group | Phase 4 | BBB |
Hydroxyurea Bahria University | Phase 4 | BBB |
Desferrioxamine B Pakistan Blood and Marrow Transplant (PBMT) Group | Phase 4 | BBB |
Tacrolimus M.D. Anderson Cancer Center | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Mitapivat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →